NCT01156545View on ClinicalTrials.gov

BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC

PHASE2CompletedINTERVENTIONAL

Enrollment

68

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

December 31, 2016

Study Completion Date

June 9, 2021

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

BIBW 2992

BIBW 2992 40mg, once a day, oral intake, every day

DRUG

simvastatin

simvastatin 40mg, once a day, oral intake, every day.

Trial Locations (1)

410-769

National Cancer Center, Goyang-si

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

National Cancer Center, Korea

OTHER_GOV